For the Inventor, By the Inventor

Enter assignee name

Hayward, CA, United States of America

Arcus Biosciences, Inc.

USPTO Granted Patents = 40

EPO Patents = 9

Forward Citations = 84

Loading Chart...

Loading Chart...

79 inventors (with patents filed for the assignee):

Manmohan Reddy Leleti (29 out of 72 patents)

Jay Patrick Powers (26 out of 126 patents)

Brandon Reid Rosen (19 out of 20 patents)

4. Kenneth Victor Lawson (18 out of 19 patents)

5. Dillon Harding Miles (18 out of 19 patents)

6. Jaroslaw Kalisiak (15 out of 33 patents)

7. Erick Allen Lindsey (13 out of 13 patents)

8. Ehesan Ul Sharif (13 out of 14 patents)

9. Joel Worley Beatty (11 out of 12 patents)

10. Jenna Leigh Jeffrey (11 out of 12 patents)

11. Eric Newcomb (10 out of 10 patents)

12. Debashis Mandal (8 out of 14 patents)

13. Laurent Pierre Paul Debien (8 out of 8 patents)

14. Samuel Lawrie Drew (7 out of 7 patents)

15. Guillaume Mata (7 out of 7 patents)

Core Competencies:

Anti-PD-1 Antibody

CD73 Inhibitors

5'-Nucleotidase Modulators

TIGIT Antibodies

Adenosine Fingerprint

HPK1 Inhibitors

Arginase Inhibitors

Tetralin Compounds

Azolopyrimidine

Pyridone A2R Antagonists

Crystalline Forms

Cancer-Related Disorders

40 patents: Sort by Forward Citations

1. 12668635 - METHODS OF TREATING SOLID TUMORS USING AN ANTI-PD-1 ANTIBODY OR A FRAGMENT THEREOF (2026-06-30),

2. 12649751 - Inhibitors of HPK1 and methods of use thereof (2026-06-09),

3. 12630562 - Piperidylurea compounds and methods of use thereof (2026-05-19),

4. 12630526 - Processes for preparing aminopyrimidine compounds (2026-05-19),

5. 12459967 - Modulators of 5'-nucleotidase, ecto and the use thereof (2025-11-04),

6. 12453738 - Treatment of oncogene-driven cancers (2025-10-28),

7. 12433836 - Parenterally administered immune enhancing drugs (2025-10-07),

8. 12415854 - Antibodies to TIGIT (2025-09-16),

9. 12410170 - 2,3,5-trisubstituted pyrazolo[1,5-A]pyrimidine compounds (2025-09-09),

10. 12384773 - Thiazole compounds and methods of use thereof (2025-08-12),

11. 12310965 - Treatment of cancer utilizing an identified adenosine fingerprint (2025-05-27),

12. 12281136 - Crystalline forms of a CD73 inhibitor and uses thereof (2025-04-21),

13. 12226425 - Inhibitors of ARG1 and/or ARG2 (2025-02-18),

14. 12195482 - Compounds as inhibitors of AXL (2025-01-14),

15. 12195447 - Azolopyrimidine for the treatment of cancer-related disorders (2025-01-14),

Arcus Biosciences, Inc. is a biopharmaceutical company based in Hayward, California, focused on developing innovative therapies for cancer treatment. The company specializes in the discovery and development of novel immuno-oncology agents, leveraging its proprietary platform to create differentiated drug candidates. Arcus aims to address unmet medical needs in oncology through its research in immune modulation and targeted therapies, contributing to advancements in cancer care and improving patient outcomes.

Profile summary based on public USPTO records.

Company Badge

USPTO Data Jan 1 1976 - Sep 29 2026

Arcus Biosciences, Inc.

40 Patents

#17 in Hayward, CA

#2,034 in California

#8,612 in US

#17,031 in the World

Hayward, CA, United States of America

Arcus Biosciences, Inc.

Forward Citations = 84

79 inventors:

Manmohan Reddy Leleti (29 out of 72 patents)

Jay Patrick Powers (26 out of 126 patents)

Brandon Reid Rosen (19 out of 20 patents)

4. Kenneth Victor Lawson (18 out of 19 patents)

5. Dillon Harding Miles (18 out of 19 patents)

Please report any incorrect information to [email protected]

Loading…